Localization of Swiss Longevity Clinic Chains in China

📌 Background

By 2026, the demand for anti-aging medical services among China's high-net-worth individuals has surged, with telomere testing and NAD+ infusions becoming core offerings, commanding prices ranging from several thousand to over ten thousand RMB per session. Switzerland possesses world-leading anti-aging medical brands and clinical standards, while local institutions lack equivalent trust endorsements, creating a window for cross-border brand and management exports. The establishment of the Swiss CLP Longevity Center in Beijing serves as a representative model for entering the Chinese market using Swiss standards.

👤 Target Customers

Middle-aged and older high-net-worth individuals who are focused on delaying aging, boosting energy, and disease prevention. They are willing to pay a premium for high-end medical experiences, covered either through out-of-pocket payments or high-end health insurance.

💰 Revenue Streams

1) Per-session fees for high-value treatments such as telomere testing, NAD+ infusions, and stem cell therapies; 2) Annual membership subscription packages for long-term clients; 3) Brand licensing and operational management services provided to channel partners.

🧮 Cost Structure

Rent and renovation costs for clinics in prime locations in Tier-1 cities; travel and remote consultation costs for Swiss expert teams; procurement of imported diagnostic equipment and consumables; compliance approval and medical safety risk management costs.

🛡️ Moat

The brand reputation and clinical system originating from Switzerland form a natural barrier; exclusive partnerships with domestic high-end medical, insurance, and private banking channels ensure continuous customer acquisition; standardized medical processes and accumulated customer data enable scalable expansion.

🔑 Keys to Success

• Establishing trust by leveraging the clinical system and brand endorsement of the Swiss headquarters
• Securing long-term repeat business through high-net-worth channels and membership models
• Building a replicable single-store model to support multi-city expansion

⚠️ Risks

• Tightening policy approvals for treatments such as NAD+ infusions and stem cell therapies
• Brand crises triggered by medical malpractice or non-compliant advertising
• Inconsistent service quality during localization affecting the reputation of the chain

🏢 Cases

• The establishment of the Swiss CLP Beijing Longevity Center and its exploration of localized operations

📊 SWOT Analysis